Trial intelligence / Profile preview

Ixazomib, Thalidomide and Dexamethasone in NDMM

NCT03608501Phase 2Withdrawn

Sponsor
Takeda
Start
Sep 2019
Primary completion
Jun 2021
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of ixazomib in multiple myeloma (MM), sponsored by Takeda. Planned start Sep 2019; status: withdrawn.

02

Drugs

ixazomib
03

Conditions

multiple myeloma (MM)

Beyond the preview

Go deeper on NCT03608501.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03608501.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call